Genmab — November 2016

[JKY_VH]

præcis

[jkj]

link til usa,s mest kendte og præcise valgstatistikerehttp://projects.fivethirtyeight.com/2016-election-forecast/

[gentogen]

Nu rekrutteres der (omsider) til det interessante studie om Daratumumab in Combination With ATRA (DARA/ATRA)https://clinicaltrials.gov/ct2/show/NCT02751255?term=daratumumab&rank=27

[Helge_LarsenPI-redaktør]

Gentogen. Tak for link. Kan du ikke lægge spørgsmål ind om studiet i Q&Achatten?

[Helge_LarsenPI-redaktør]

På forhånd tak.

[gentogen]

http://www.bioportfolio.com/resources/trial/156979/Daratumumab-in-Combination-With-ATRA.html

[JKY_VH]

tak gentogen

[Bulder]

Så kan du godt slette mit spørgsmål nr. 2 til q&a, Helge

[Helge_LarsenPI-redaktør]

Det tænkte jeg lige på. Done.

[Helge_LarsenPI-redaktør]

Du må gerne stille uddybende spørgsmål ligesom jeg skrev til Gentogen.

[jkj]

nogen der kender det dansk klokkeslæt for abstract frigivelse imorgen ?

[Bulder]

Nu mangler vi bare at der kommer nyt om dara+Tecentriq-studiet i en solid tumor, så vi osse slipper for at spørge om det.

[Bulder]

Kl 14

[Sukkeralf]

Fra Gilead Q3 transcript:

[Sukkeralf]

As you know, we are also focused on augmenting our portfolio with external opportunities, particularly in the field of oncology. However, our interest in partnerships and potential acquisitions is not limited to oncology, and we are considering opportunities where there is strong science and where we see the possibility of developing a truly differentiated product

[Sukkeralf]

we're still very actively evaluating opportunities. We're actively evaluating a series of different partnerships

[Sukkeralf]

So we're currently very, very active. We'll do things when they make sense for us and not before then. And that's really as much as I can say.

[2311leeds]

Hvad tid kommer regnskab fra Genmab??..Kan se herinde der står kl.16...Har hørt ude i byen at det først er efter luk på den danske børs..

[jkj]

ca 17.05

[Sukkeralf]

Discipline has both components to it. There are a number of things that I think are probably too early for us to take part in. There are a number of things that I think are just overpriced. And so it's been a combination of those two things looking backward. Going forward, we'll have to see what makes sense for us and where we're willing to go to bring in new products.